Allink Biotherapeutics Secures $42M to Support the Development of Bispecific Antibody and ADC Pipeline
Shots:
- Allink Biotherapeutics has secured $42M in Series A financing to support the development its bispecific antibody and ADC portfolio
- The financing round was led by Lanchi Ventures, with participation from Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, and existing investors Gaorong Ventures and Med-Fine Capital
- The Series A funds will advance global P-I clinical development of ALK201 and ALK202 across Australia, the US & China, expand the oncology and immunology portfolio, develop the bispecific antibody and ADC platform as well as drive global footprint expansion
Ref: Allink Biotherapeutics | Image: Allink Biotherapeutics
Related News:- Arrowhead & Sarepta Sign a Global Licensing and Collaboration Agreement for Multiple Clinical and Preclinical Programs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
